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Despite advances in the treatment of Alzheimer’s disease (AD), there is currently no
prospect of a cure, and evidence shows that multifactorial interventions can benefit
patients. A promising therapeutic alternative is the use of transcranial direct current
stimulation (tDCS) simultaneously with cognitive intervention. The combination of these
non-pharmacological techniques is apparently a safe and accessible approach. This
study protocol aims to compare the efficacy of tDCS and cognitive intervention in a
double-blind, randomized and factorial clinical trial. One hundred participants diagnosed
with mild-stage AD will be randomized to receive both tDCS and cognitive intervention,
tDCS, cognitive intervention, or placebo. The treatment will last 8 weeks, with a
12-month follow-up. The primary outcome will be the improvement of global cognitive
functions, evaluated by the AD Assessment Scale, cognitive subscale (ADAS-Cog).
The secondary outcomes will include measures of functional, affective, and behavioral
components, as well as a neurophysiological marker (Brain-derived neurotrophic factor,
BDNF). This study will enable us to assess, both in the short and long term, whether
tDCS is more effective than the placebo and to examine the effects of combined
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therapy (tDCS and cognitive intervention) and isolated treatments (tDCS vs. cognitive
intervention) on patients with AD.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02772185—May 5,
2016.
Keywords: clinical trial, dementia, neuropsychology, non-pharmacological approaches, transcranial direct current
stimulation, neuromodulation
INTRODUCTION
Alzheimer’s disease (AD) is characterized by a progressive
deterioration of cognitive functions, impacting the autonomy
of patients in performing their activities of daily living (ADLs;
Buschert et al., 2010). Pharmacological approaches only provide
moderate symptom control, provisionally improving cognition
or slowing down cognitive decline (Massoud and Gauthier,
2010). In this context, the earlier the diagnosis of probable
AD is performed, the better the patient prognosis will be as
cognitive intervention can be applied in the early stages of the
disease (Fernández-Calvo et al., 2015; Kawashima et al., 2015).
For example, memory, executive functions and attention may be
relatively improved when adequate support is provided (García-
Alberca, 2015). However, intervention specificity, best candidate
selection for different types of protocols, and whether benefits
can transfer to untrained cognitive domains are still controversial
topics (Alves et al., 2013; Fernández-Calvo et al., 2015).
Thus, multimodal intervention makes it possible to prevent
(Olanrewaju et al., 2015) or delay the progression caused by
the disease (Olazarán et al., 2010). Currently, non-invasive
neurostimulation techniques such as transcranial direct current
stimulation (tDCS) have been used to delay the cognitive deficits
and to decrease the functional impairment of patients with
dementia (Andrade et al., 2016; André et al., 2016; Gonsalvez
et al., 2017). tDCS is a low-cost, portable and safe tool that
induces plasticity via electrical stimulation using a low-intensity
current and a continuous flow through the brain. This pattern
of electricity modulates cortical activity without directly acting
on neurons, which decreases the risk of serious adverse effects
(Boggio et al., 2011).
The neurobiological basis of AD recovery after
neurostimulation is the ability of tDCS to induce long-term
synaptic changes. The effects perceived during stimulation
are apparently associated with changes in the subliminal
membrane resting levels that modulate the input-output
curve. Conversely, prolonged effects would act on GABAergic
activity, the glutamatergic system, long-term potentiation
(LTP) and long-term depression (LTD) mechanisms related
to plasticity (Yu et al., 2015). Studies in mice with a similar
disease to AD show tDCS effects on several of these factors,
also including axonal activation and alteration in the cellular
transmembrane potential, and consequently neurotransmitter
balance (Ruohonen and Karhu, 2012).
In a critical review of the use of tDCS combined with
cognitive rehabilitation, Cappon et al. (2016) concluded that
many studies failed to assess whether improvement in a
specific task transfers to ADLs in AD treatment. The authors
indicate it is imperative to discriminate between increased
performance on a specific cognitive task and recovery in
more general ADLs demanding that cognitive function. This
suggests the importance of including other cognitive domains
in both the evaluation and the treatment protocol, such as
memory and executive function. Consistent results reported
by systematic reviews and meta-analyses have shown that
overall cognitive stimulation, a cognitive intervention based
on a range of different cognitive activities (Clare and Woods,
2004), promotes better cognitive and neuropsychiatric benefits
in patients with AD than cognitive training of specific domains
(e.g., memory; Buschert et al., 2010; Spector et al., 2012;
Woods et al., 2012; Bahar-Fuchs et al., 2013; Huntley et al.,
2015).
Nevertheless, some studies only evaluated the effect of
different forms of neurostimulation without associating
neurostimulation with cognitive intervention protocols (Boggio
et al., 2009, 2011; Bystad et al., 2016b). To date, three studies have
evaluated the combined use of tDCS and cognitive rehabilitation
(Cotelli et al., 2014; Penolazzi et al., 2015; Andrade et al., 2016). A
common limitation to these studies is the use of a brief protocol
of tDCS (only 10 sessions), without long-term follow-up of
participants (longer than 6 months). Because AD is a progressive
disease, monitoring participants for long periods of time is
crucial to assess whether the therapeutic effect is sustained to
enable the tested protocol to be transferred to clinical practice.
However, a thorough search of the relevant literature yielded
no articles analyzing tDCS efficacy associated with cognitive
intervention in producing physiological and behavioral changes
in patients over time (12 months).
Additionally, the current application moment, meaning
whether it is applied before, during, or after cognitive
intervention, may also cause variability in the results (Cappon
et al., 2016). In a systematic review and meta-analysis assessing
the effects of non-invasive neurostimulation on healthy elderly
individuals and patients with AD, the authors observed
that ‘‘the optimal timing for administration of tDCS’’ varies
according to the physiological and pathological aging (Hsu
et al., 2015). The use of neurostimulation before task execution
can produce robust effects on healthy elderly individuals.
Conversely, AD group shows more pronounced effects for
studies that apply the stimulation during task execution
compared to studies that uses the stimulation before task
execution.
Another key point is that most studies involving tDCS in AD
typically assess neurostimulation effects on only one cortical area.
This aspect is worrying because the pathological characterization
of dementia differs from other neurological diseases, wherein
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only one brain region should be modulated such as stroke or
depression (Iannone et al., 2016; Ilíc et al., 2016). In AD, the
clinical symptoms are not restricted to memory loss, suggesting
the involvement of more complex neural networks (Lesuis et al.,
2016; Ossenkoppele et al., 2016). Thus, choosing only the frontal
or temporal region could limit the scope of treatment and result
in the absence of cognitive gains, as found by Bystad et al.
(2016a) who observed no improvement in the cognitive domains
of patients when applying tDCS over a short period (10 days)
exclusively on the left temporal cortex. Thus, it is important
that the therapeutic protocol of tDCS in AD should encompass
another cortical locus.
Related to this, other factors must be analyzed such as the
stimulation duration. Although the standard tDCS protocol only
involves application in one cortical area per session of 20 min
(Nitsche et al., 2008), some authors also reported that 10 min of
tDCS application in one (Drummond et al., 2017) or two cortical
regions, one after the other (frontal and parietal cortex; Jones
et al., 2015), is sufficient to promote neuromodulatory effects.
In addition, Fricke et al. (2011) prove that the use of repeated
applications of tDCS generates long-lasting effects.
Although there are several studies involving non-invasive
neurostimulation and cognitive training in the treatment of
AD, the cognitive and functional effects remain unclear. Recent
reviews suggest larger samples to investigate the synergistic
effects of these two therapies, with control of confounding
variables and with realistic parameters, aimed at clinical practice
(Hsu et al., 2015; Zhao et al., 2017).
Accordingly, we propose that stimulating different brain
regions specifically related to the neuropathology of AD along
with repeated applications of 10-min tDCS in each session
may be an option to achieve short- and long-term effects.
However, at this time we have only just drawn up a study
protocol and these hypotheses can only be tested in the main
clinical trial that we aim to perform. In addition, no reports of
factorial randomized clinical trials using with tDCS and cognitive
intervention stimulating different cortical regions with a 10-min
interval in each, and with follow-up for AD-related outcomes
have been found to date.
In this way, we designed the Neurostimulation combined
with Cognitive Intervention in AD (NeuroAD) clinical study,
a phase II/III trial, to address the safety and efficacy of tDCS
and cognitive intervention in the treatment of AD. Based on
the aforementioned data, which suggest beneficial effects of
both cognitive intervention and tDCS on patients with AD,
we hypothesize that combining both treatments modulates
cortical activity and improves the long-term clinical symptoms
of patients, manifested as increased cognition and functional
capacity and reduced affective and behavioral changes.
MATERIALS AND EQUIPMENT
Overview
NeuroAD is a factorial, placebo-controlled, double-blind and
randomized clinical trial in which 100 patients at the mild stage
of AD are randomly assigned to four groups: 1—active tDCS and
active cognitive intervention; 2—sham tDCS and active cognitive
intervention; 3—active tDCS and placebo cognitive intervention;
and 4—sham tDCS and placebo cognitive intervention. All of
the patients will be subjected to tDCS and cognitive intervention
applied for 24 workdays. At the end of the trial, patients who
received active tDCS and achieved clinical response will be
invited to maintain tDCS bimonthly for 12 months, as part
of a long-term study of tDCS for AD; those who did receive
sham tDCS and did not respond will be offered 24 open-label
daily sessions of tDCS (crossover study); finally, those who
showed response with cognitive intervention (real or placebo)
and sham tDCS will be referred to other neuropsychological
centers specialized in treating dementias in our Institution.
Randomization and Blinding
The participants will be randomized into 1:1:1:1 blocks using
the random number generator of an open-access randomization
software program1. This sequence will be remotely performed
by a blind researcher not involved in other research procedures.
After the randomization process, a blinded staff member
will perform patient allocation between the groups. Hidden
allocation will be performed with closed, sealed and sequentially
numbered envelopes. The participants will be identified by codes
and will also be blinded; that is, they will ignore the arm of
the study to which they will be allocated. The evaluation and
treatment will be performed by independent researchers, who
will identify the patients by their respective codes and will be
blinded to the other research procedures. Data analysis will
be performed by a professional not involved in any stage of
patient recruitment, screening, assessment, or intervention. The
effectiveness of the masking will be assessed after completing
the treatment by interviewing the raters, who will be asked what
type of treatment (active or placebo) they believe that the patient
received. The relatives of participants will also be blinded and
asked, at the end of the treatment, to which group they believe
that the patient was allocated. The patients will also be asked
questioned about which group they believe have been allocated.
We decided to assess the effectiveness of the blinding by asking
the relatives and/or caregivers of the patients because the patients
have mild AD.
Attrition and Adherence
Attrition will be considered under the following conditions: (a)
two consecutive or three alternating absences from treatment
sessions in a one-month period; (b) the inability to complete
the post-test and follow-up; and (c) the development of any
disabling condition preventing the participant’s participation in
the study. Regarding adherence strategies, sessions missed until
the established limit will be reset the following week. Flexible
therapy hours will also be offered, and the relatives of the patients
will be directly contacted by telephone to confirm the dates of
evaluation, thereby reinforcing treatment adherence (Brunoni
et al., 2011). Additional measures to avoid dropouts will also be
applied, including periodic assessments of treatment satisfaction,
discussion of difficulties in continuing treatment (for example,
1www.random.org
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logistics of the trips to the laboratory) and attempts to resolve
and avoid possible problems that may affect adherence to and
continued participation in the study.
Safety
To investigate adverse effects, the participants will be asked at
the end of each session whether they experienced effects such as
‘‘tingling’’, ‘‘burning’’, ‘‘headache’’, ‘‘somnolence’’, among others
and subsequently asked the intensity of this sensation (1—none,
2—mild, 3—moderate, 4—strong) and whether this effect could
be related to stimulation using a Likert scale ranging from 1
(unrelated) to 5 (strongly related). Although tDCS is considered
a safe technique that has been applied to several neurological
and psychiatric disorders for years (Nardone et al., 2015), if the
patient exhibits any severe impairment or discomfort, treatment
will be discontinued, and medical assistance and physical and
psychological therapy will be provided to control potential
problems and promote recovery.
Participants
The evaluation and intervention procedures applied to the
participants will be performed by trained professionals with
experience in AD patient management. The team will consist of
neuropsychologists, geriatricians, neurologists, occupational and
speech therapists, biomedical and physiotherapists.
Inclusion Criteria
The participants will be included according to the following
eligibility criteria: (a) being 50–90 years of age; (b) having a
diagnosis of dementia [criteria of the Diagnostic and Statistical
Manual of Mental Disorders—Fourth Edition (Text Revision,
DSM-IV-TR; American Psychiatric Association, 2000)] and of
probable AD according to the National Institute of Neurology
and Communication Disorder and Stroke-The AD and Related
Disorders Association Criteria (NINCDS-ADRDA; McKhann
et al., 2011); (c) having a score = 1 in the Clinical Dementia Rating
(CDR; Morris, 1993); (d) a score higher than 18 points in the
Mini-Mental State Exam (MMSE; Folstein et al., 1975); (e) using
acetylcholinesterase inhibitors (AChEI) and/or memantine for at
least 3 months prior to screening; and (f) not having received
regular cognitive intervention in the 3 months prior to the start
of this clinical trial.
Exclusion Criteria
Participants (a) with unstable medical conditions, serious
metabolic and/or cardiac diseases, alcoholism, focal neurological
disorders (e.g., epilepsy, stroke, brain injury or tumor) and
associated psychiatric disorders; or (b) using hypnotics and
benzodiazepines up to 2 weeks before the start of the study;
or (c) with any condition (e.g., communication, sensory
or motor deficits) that could significantly interfere with
the neuropsychological assessment or to receive a cognitive
intervention protocol of the trial will be excluded from
the study. In addition, participants with contraindications to
fMRI scans such as claustrophobia, presence of electronic
implants (transient or definitive pacemaker, cochlear implant),
or the presence of intracranial aneurysm clips will also be
excluded. Finally, exclusion criteria relating to contraindications
of neurostimulation will be applied, following the safety
guidelines: (a) using psychoactive drugs, as stated in the
recommendations; (b) having implanted metallic or electronic
devices; (c) having a cardiac pacemaker, seizures, acute eczema
under the electrodes; and (d) the presence of tumors, epilepsy,
or substance abuse (Nitsche et al., 2003; Brunoni et al.,
2011).
Patient Recruitment
A sample of volunteer participants will be recruited from
neurorehabilitation clinics, community programs dementia
treatment centers and the Aging Neuropsychology Service
(SENE) of the Federal University of Paraíba. The clinical trial
will also be promoted in websites, newspapers and radio.
Furthermore, healthcare professionals from the aforementioned
sites will promote the study among patients with probable AD.
After signing the informed consent form, the data of patients
interested in participating in the clinical trial will be analyzed,
and the patients will be contacted for inclusion in the study,
according to the eligibility criteria.
Intervention
tDCS
Anodal tDCS (2 mA, 30 min) will be applied three times a week
for 2 months (24 sessions). The TCT-Research neurostimulator,
developed by TransCranial Technologies (Hong Kong, China)
will be used. The rubber electrodes are involved in saline-soaked
sponges and fixed with a headband. We will use a specific
electrode (4 × 4 cm) to avoid covering of adjacent areas by
the tDCS electrode (current density = 0.13 mA/cm2). After the
electrodes placement, the stimulation duration, current intensity
and both ramp up/ramp down times will be programmed.
To avoid that stimulation fail, the impedance levels will be
checked (constant under 5 kΩ). Proper and reliable stimulation
requires good contact under the electrode area to a consistently
conductivity through the circuit. In the case of stimulation
failures, the problem can be solved by reapplying a saline solution
or conductive gel on the holding bags, or by parting the hair
beneath electrodes, as reported in previous studies. To ensure
that any discomfort occurs, the participants will be accompanied
during all experiment procedures (DaSilva et al., 2011; Thair
et al., 2017).
The active current will be applied to six cortical areas
affected by AD. These sites are primary centers involved in
the manifestation of clinical symptoms of the disease, including
the left and right portions of the dorsolateral prefrontal cortex,
related to short-term and long-term memory, judgment ability
and executive functions; Broca’s area and Wernicke’s area,
located in the temporal lobe, responsible for language; and the
right and left somatosensory association cortex, in the parietal
lobe, related to topographical and spatial orientation and praxis
(Figure 1). The choice of these areas follows previously-tested
neurostimulation protocols in patients with AD (Bentwitch et al.,
2011; Rabey et al., 2013).
We will subdivide the neuromodulation protocol into A and
B to stimulate the areas with the same number of sessions:
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FIGURE 1 | Montage of transcranial direct current stimulation (tDCS) sessions
(Left Hemisphere). (A) F3—Dorsolateral prefrontal Cortex; (B) F5—Broca’s
area; (C) CP5—Wernicke’s area; (D) P3—Somatosensory association cortex.
Electrode position nomenclature of 10/20 System (Electroencephalography).
(1) protocol A will involve stimulating Broca’s area (F5),
Wernicke’s area (CP5), and the right dorsolateral prefrontal
cortex (F4); and (2) protocol B will involve stimulating the left
dorsolateral prefrontal cortex (F3) and the right and left portions
of the parietal cortex (P4 and P5), according to the international
10–20 electrode nomenclature system. The protocols will be
applied alternately; that is, protocol A will be applied in one
session and protocol B in the next to stimulate the six cortical
areas. The counterbalancing is justified to prevent higher current
intensity applied to the patient’s scalp with the simultaneous
stimulation of multiple areas, which could provoke painful
stimuli and would not be in line with the technique guidelines
(Furubayashi et al., 2008; Bikson et al., 2016).
The location of the protocol’s target regions to be applied
on the day (either protocol A or B) will be performed before
we begin the procedure. Thus, all regions are marked on
the participant’s scalp in advance, avoiding delays during the
treatment session. The instrument will cease after the first
10 min, and the electrodes will be positioned in the next region.
As they are alreadymarked, moving from one location to another
will take less than 1 min (20–35 s estimate). Therefore, the
treatment session will last at least 28 min, considering two brief
stops for positioning the electrodes. We did not find evidence
in the literature of interruptions of less than 1 min during
electrode exchange or positioning, which could result in ablation
or interference in the anode or current cathode effects.
Each aforementioned area will be stimulated for 10 min,
totaling 30 min of treatment (three areas stimulated per session).
The reference electrode 35 cm2 (5 × 7 cm) will be placed in the
contralateral supraorbital area. The placebo stimulation protocol
will be identical, although the device will cease to emit a current
30 s after starting the stimulation. Thus, the active current is
simulated (slight tingling and itching sensation) for a short
period, and the effects disappear shortly after the start of the
stimulation (Nitsche et al., 2003; Gandiga et al., 2006).
An fMRI of all participants will be obtained before the
experiment. The FSL software (FMRIB’s Software Library,
University of Oxford, UK) will be used to transform coordinates
for brain areas for each subject individually. The individual
structural images will be initially converted intoMNI coordinates
(standard Montreal Neurological Institute) and then the MNI
coordinates will be inversely transformed to the original imaging
space. These values will be obtained by converting Talairach
coordinates to the MNI space (Paus, 1996). These coordinates
will be used to guide the frameless stereotaxy (Brainsight
system, Rogue Research, Montreal, QC, Canada). The location of
target regions will be performed by an experienced and trained
professional. Procedures will be repeated at each treatment
session for all participants involved.
Cognitive Intervention
The active protocol, involving 72 cognitive activities,
was developed by neuropsychologists specialized in the
non-pharmacological treatment of AD and will be applied
by professionals trained in the management of this cognitive
intervention program. This program is supported by similar
studies of cognitive intervention in this population (Spector
et al., 2001; Fernández-Calvo et al., 2010, 2015).
The cognitive activities with correspondence to the stimulated
areas were developed using validated paradigms: (a) syntax and
grammar tasks for Broca’s area and comprehension of lexical
meaning and categorization for Wernicke’s area; (b) verbal and
spatial working memory tasks for the dorsolateral prefrontal
cortex; and (c) Spatial attention and perceptual–motor tasks
(shapes and letters) for the somatosensory association cortex
(e.g., Dobbs and Rule, 1989; Gabrieli et al., 1996; Buck et al.,
1997; Thompson-Schill et al., 1997; Grossman and Rhee, 2001;
Grossman et al., 2002; Love and Oster, 2002; Hao et al., 2005;
Sparing et al., 2008; Bellgowan et al., 2009; Hamidi et al., 2009;
Nyberg et al., 2009; Belleville et al., 2011; Hampstead et al.,
2011). Most of these paradigms were applied in studies with AD
patients or with neurostimulation techniques. Similar tasks based
on the same paradigms were tested in studies that combined
neuromodulation and cognitive intervention for people with AD
(e.g., Bentwitch et al., 2011). However, some of these tasks have
been adapted from the original paradigms to be used in pencil-
and-paper activities. Some of the cognitive activities that will
be used with the participants of the clinical trial are described
below:
• Cognitive activities associated with Broca’s area. This set
of tasks tries to activate verbal language production through
stimulating syntactic and grammatical language processing:
– Repeating words, pseudowords and phrases. The
participant should repeat the words (concrete nouns
that vary in size and frequency), pseudowords and phrases
created from the previous stimuli, which are presented
orally.
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– Naming. The participant is instructed to retrieve the name
of the displayed object. If the participant does not name it
(e.g., bed), then both semantic (e.g., a piece of furniture) and
phonological tips will be provided (e.g., begins with ca).
– Description-Narrative by confrontation. This task consists
of stimulating expressive conversation language based on
visual stimuli. The participant will be shown a thematic slide
about a situation and the situation should describe what
they see, producing a story. It is about creating phrases and
producing descriptive narratives and not simply naming
objects in the image. For example, from the thematic sheet 1:
‘‘The city’’ can be elaborated into a story like the following:
The girl went out to the street . . . She was going to buy
. . . She arrived at the traffic light . . . She crossed the street
without looking at the traffic lights . . . The driver . . . had to
brake abruptly . . . The blind man was in the same . . .’’
• Cognitive activities associated with Wernicke’s area. This
type of activity focuses on triggering language comprehension
using the lexical/semantic system:
– Sentence comprehension. This task consists of silently
reading incomplete sentences and the participant should
write the word that completes the sentence (e.g., dogs
have four...). If the participant does not give an answer,
four words (e.g., fingers, legs, legs, eyes) are shown and the
participant must select the one that best serves to complete
the sentence. One variant of this task is understanding
contextualized phrases, which consists of understanding
phrases contextualized by images. The participant should
read a sentence, analyze the images and mark the one that
best represents the read sentence (e.g., the phrase ‘‘The
driver drives the bus’’ appears next to four pictures, in which
only one corresponds to the sentence read).
– Association of nouns and adjectives. In this task, different
nouns and adjectives are presented and the participant
should join the most appropriate adjective for each word
with the arrows (e.g., teeth, green, hair, fair, litigation,
maturity, grassland, white, fruit, gray-haired).
– Grammatical class change. This task consists of exchanging
nouns for verbs and verbs for nouns. In changing
the condition from noun to verb, participants are
instructed to read the noun and retrieve the verb (e.g.,
Forgiveness = forgive). In the case of not issuing a response,
a list of verbs will be shown in which the participants
will retrieve the verb corresponding to the noun. In the
condition of verb for noun, participants should read
the verb and retrieve the corresponding noun (e.g.,
amar = lover).
• Cognitive activities associated with left or right dorsolateral
prefrontal cortex. These activities are focused on promoting
manipulation of verbal and spatial knowledge, associative
processes and information selection:
– Object-location memory. This task includes the coding
and recognition stages of alternating stimuli or sites. In the
coding and recognition phases, different sequences of six
stimuli (shapes, colors, faces and letters) are presented. The
stimulus memory task requires the subsequent recognition
of target stimuli regardless of location, while the spatial
task requires the coding and subsequent recognition of the
location at which the stimuli were presented.
– Delayed match-to-sample tasks. This type of activity
requires visual pairing with the delayed model. The
procedure consists of presenting a stimulus that the
participant must remember (sample). Then, the stimulus is
withdrawn and the participant must identify the stimulus
that exactly corresponds to the sample (comparison
stimulus) among a set of stimuli. The target and comparison
stimuli can be simple (pictures of shapes, colors, letters,
faces and objects) or complex (abstract). Thus, different
variations of this task were created.
– Selection of semantic knowledge. This task consists of
classifying designs of common objects while taking into
account different selection conditions such as a specific
attribute of the object’s representation (large, small, light,
heavy, artificial, natural, expensive, cheap) or according to
the object’s name (spider, hammer). As an example of the
first condition, a drawing of a car is presented together with
the word car, whereas in the second condition the word
spider is next to the drawing of a swan. In both activities, the
participants should determine whether this classification is
correct or not.
– Associative face memory. This task requires encoding
and recognizing associations between faces and names. In
the first condition, subjects visualize paired faces with an
unusual name. After the participant observes four pairs of
faces with their names, one face and four name options are
displayed.
– N-back task. This task requires the participant to decide
whether each heard or seen sequential stimulus matches
what was heard or seen n items before. The stimuli
can be letters, numbers, words (auditory condition) or
photographs of objects (animals, fruits, tools, household
utensils), and three conditions are used for each type of
stimulus (n = 0, n = 1 and n = 2). For example, in condition
n = 0, the participant must repeat the letter or (number)
immediately after listening to it [C (‘‘C’’), F (‘‘F’’). T (‘‘T’’),
S (‘‘S’’), B (‘‘B’’)]; in n = 1, the participant should say the
letter they heard immediately before [C (‘‘none’’), F (‘‘C’’).
T (‘‘F’’), S (‘‘T’’), B (‘‘S’’)]; and in n = 2, the participant has
to say the letter they heard two times before [C (‘‘nothing’’),
F (‘‘nothing’’), T (‘‘C’’), S (‘‘F’’), B (‘‘S’’)].
– Encoding and retrieving word meaning. This task requires
remembering words using a semantic coding strategy. The
implemented stimuli are concrete (e.g., cat, notebook) and
abstract nouns (e.g., beauty, fear) and the participant must
judge whether each word refers to something abstract or
concrete. Once the judgment of each word presented has
been completed, the participant is asked to remember the
most words they can.
• Cognitive activities associated with somatosensory
association cortex. These exercises aim to stimulate cognitive
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components related to perception (e.g., recognition of simple
and complex objects or spatial relationships between them),
spatial attention (e.g., visual scanning and tracking), visual
episodic memory (e.g., task retrieval), visual working memory
(task recognition) and motor skills or spatial reasoning:
– Match-to-sample task. This activity requires simultaneous
visual matching capability. It consists of simultaneously
displaying a simple or complex visual stimulus (sample)
and four comparison stimuli. The participant should select
the stimulus that exactly corresponds to the sample. The
target and comparison stimuli can be simple (line drawings
or pictures of shapes, letters, faces, or objects) or complex
(abstract). Thus, different variations of this task were
created.
– Visual search. This type of activity requires the selection
of relevant stimuli (target) and ignoring irrelevant
(distracting) stimuli. The task requires the participant
to detect the predefined target stimuli in a matrix in the
midst of a series of distracting items. Different versions
of this task were created using different types of stimuli
(pictures and line drawings of shapes, letters, or objects).
Two classes of stimuli are present in some situations in the
matrix, requiring them to link characteristics to perform
the activity. For example, the target is a vertical red bar and
the distractors are vertical green bars and red horizontal
bars.
– Overlapping figures. This task requires
identifying overlapping stimuli (shapes, letters
and line drawings) with different levels of
noise.
– Visual Tracking. This task requires following a curved
and irregular line with their eyes from one attached
point to another attached point associated with numbers
or letters. For example, the participant must choose
a letter (or number) and follow the connecting line
to its destination number (or letter) using only their
eyes, without paying attention to the lines that they
cross.
The 72 cognitive activities distributed by the stimulated areas
each week were organized in a book, which includes the
description (objective and procedure) and the material needed
for each activity. All occupational therapists will be trained to
apply each cognitive activity in the same way before beginning
the clinical trial. Monitoring sessions will be held monthly to
solve any problems in the intervention.
All activities will be applied simultaneously with
neurostimulation, that is, the occupational therapist will
perform activities involving operational memory while the
operational memory area is stimulated with tDCS; cognitive
intervention activities will focus on language when stimulating
the language cortical area, and so on so that neurostimulation
is related to the cognitive task tested. The 10-min time per
region will also apply to the cognitive intervention protocol,
since tasks will be scheduled to last up to this time. Thus, when
the device ceases to emit the current, the cognitive task will
not be ‘‘interrupted’’, but rather finalized, because we expect
to perform three different types of exercises over 30 min, each
lasting 10 min. The pilot studies will allow us to calibrate
a number of cognitive exercises necessary for each of these
activities within each intervention session. Since the electrode
change for a new region will be performed in less than 1 min,
we think the interruption effect is minimal. Nevertheless,
in order to minimize possible effects through the cognitive
activity intervention, participants will be informed of the three
groups of activities that will be performed at the beginning
of each session, and the duration of each activity. However,
even though the patient can perform them in a slower or faster
time than this, we expect that this variation should be minimal
because the total time is equivalent to the defined time in the
protocol.
Regarding the placebo protocol of cognitive intervention,
participants will watch short videos while receiving tDCS. The
videos of the sham cognitive stimulation will also be chosen based
on this time limit of 10 min. The researcher responsible for the
cognitive intervention will stand next to the participant during
the session and make comments unrelated to the treatment,
including asking what the patient found from the video, whether
it was pleasurable, and whether they are feeling comfortable.
Outcome Measures
All outcome measures for AD patients will be done in 60-min
session, pre and post intervention phase. The Reliable Change
Index (RCI) will be used to minimize the practical effects, as
described in the ‘‘Proposed Analysis’’ section.
Primary Outcome
The ADAssessment Scale, cognitive subscale (ADAS-Cog; Rosen
et al., 1984), will be used to analyze the primary outcome. The
ADAS-Cog consists of an 11-item cognitive subscale related
to memory, orientation, visuo-spatial ability, language and
ideational praxis. The main cognitive domains assess memory,
language, praxis and understanding. The instrument has inter-
rater reliability values ranging from 0.947 to 0.99 and test-retest
values ranging from 0.59 to 0.92, and it is considered reliable for
application to patients with AD. Scores range from 0 to 70, with
higher scores reflecting more cognitive impairment.
Secondary Outcomes
The Neuropsychiatric Inventory Questionnaire (NPI-Q;
Kaufer et al., 2000)
This instrument is completed by caregivers and provides
information regarding 12 typical behavioral and psychological
symptoms that may occur in patients with dementia. In this
study, we used a severity rating (1 = mild, 2 = moderate,
3 = severe) for identified symptoms, deriving a severity
score (range 0–36), with zero indicating no neuropsychiatric
symptoms. The reliability and validity of this modified NPI score
have previously been established.
The Cornell Scale for Depression in Dementia (CSDD;
Alexopoulos et al., 1988)
This instrument is a 19-item clinician-administered instrument
that uses patient and caregiver information to assess symptoms
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of affective disturbance in patients with dementia. It assesses
mood-related signs, behavioral disturbances, physical signs,
cyclic functions and ideational disturbances. Each item of the
Cornell Scale for Depression in Dementia (CSDD) is evaluated
on a three-point scale (0–2) that reflects symptom severity.
Hence, the total score ranges from 0 to 38, with higher scores
depicting greater depression. The reliability and validity of this
CSDD score have been previously established.
The Disability Assessment for Dementia (DAD; Gélinas
et al., 1999)
This instrument is an informant-based scale composed of
17 items pertaining to basic ADLs (hygiene, dressing, continence
and eating) and 23 items pertaining to instrumental ADLs
(meal preparation, telephoning, going on an outing, finance and
correspondence, medications and leisure and housework). Each
item is evaluated for initiation, planning and effective execution.
To avoid bias toward certain activities (e.g., meal preparation),
nonapplicable questions are omitted from the final score, and
the score is reported as a percentage. The maximum total score
is 100, with lower Disability Assessment for Dementia (DAD)
scores denoting greater impairment. Basic ADL and instrumental
ADL subscores are included in the analysis, in addition to total
DAD scores (Bahia et al., 2010).
The Zarit Burden Interview (Zarit et al., 1985)
This instrument (22 items) is used to measure caregivers’
perceived burden in diverse domains (Zarit et al., 1985). The scale
was validated for the Brazilian population (Taub et al., 2004),
with acceptable internal reliability (Cronbach’s alpha), ranging
from 0.77 to 0.88. The score responses range from 0 (never) to 4
(almost always) to prevent discrepancies with the original scale
scores. Total scores range between 0 and 88 points, with higher
scores reflecting higher caregiver burden.
Given the possibility of biases associated with this procedure,
we perform the neuropsychological assessments on two
consecutive days, respecting the limits of patients and their
caregivers and offering them breaks for rest and hydration,
whenever necessary.
Brain-Derived Neurotrophic Factor (BDNF)
Serum brain-derived neurotrophic factor (BDNF) levels will
be measured with the BDNF Emax Immunoassay system kit
(Promega, Madison, WI, USA), according to the manufacturer’s
instructions. Blood samples will be collected and allowed to
coagulate for 1 h at room temperature, followed by 1 h at 4◦C.
Serum will be separated by centrifugation at 2000 g for 10 min at
4◦C, put in an aliquot and stored at −80◦C until used in 0.2 ml
tube strips.
Ethics, Participant Consent and Study
Registration
This study is being carried out in accordance with the
recommendations of National Health Council with written
informed consent from all subjects. All subjects will provide
written informed consent in accordance with the Declaration
of Helsinki. The protocol was approved by the Institutional
Ethics Committee on Human Research. In case of inability
to understand the instructions or due to the presence
of anosognosia, both the participant and caregiver will
sign the informed consent form. The study was approved
by the Brazil’s National Committee for Ethics in Research
(CAAE: 44388015.7.0000.5188) and publicly registered in the
ClinicalTrials.gov database (NCT02772185). The trial protocol
follows the SPIRIT (Standard Protocol Items: Recommendations
for Interventional Trials) guidance for protocol reporting (Chan
et al., 2013).
Sample Size
The sample size was estimated based on previous studies that
used paired tDCS groups in treating AD (Ferrucci et al., 2008;
Boggio et al., 2012). The power calculations determining the
number of participants in each group were made in relation to
the expected change in ADAS-Cog because this instrument is
commonly used in studies involving cognitive evaluation in these
patients (Vellas et al., 2007; Balietti et al., 2017; Xiao et al., 2017).
The expected significant improvement is reaching 3.76 points
in the mean, with an standard deviation (SD) of 1.32 points,
according to Rabey et al. (2013). Therefore, a calculation
considering the level of p < 0.05 and 90% power as significant
suggests that at least 10 patients would be necessary in each
group to detect whether the difference found matches the
effect of the active or simulated treatment. Considering the
application of tDCS in multiple areas, stimulation time and
the possibility of sample losses throughout the study (dropout,
inability to continue treatment, death), 25 patients per group will
be included, totaling 100 participants.
Proposed Analysis
Intent-to-treat analysis will be used; that is, all participants
will be included in the analysis, including those who drop out
before completing the treatment. However, high or different rates
of dropouts between the treatment arms may lead to biases.
Thus, a sensitivity analysis will be performed with different
assignment procedures to assess the value of the data. The best
strategy resulting from the following methods will be chosen: last
observation carried forward, complete case analysis, likelihood-
based methods, or multiple imputation.
Descriptive statistics will be used to describe clinical
and sociodemographic characteristics and the primarily and
secondary outcomes of each group at the baseline. The groups
will be compared by analysis of variance (ANOVA), for
continuous variables, or the chi-square test, for categorical
variables.
The primary outcome will be examined by split-plot ANOVA
with one dependent variable (ADAS-Cog score) and two
independent variables, namely, one intra-group variable and one
inter-group variable. The within-subject variable will include
time (baseline, post-treatment and 12-month follow-up), and
the effects of the treatment condition (active or placebo tDCS;
active or placebo cognitive intervention) will be examined as a
between-groups variable. Post hoc comparisons using Bonferroni
correction will be performed where appropriate. Finally, the
effect sizes regarding inter-group comparisons will be calculated
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using the eta squared (η2), and effect sizes regarding intra-group
comparisons will be calculated by means of Cohen’s d using
Hedges’ correction (Fritz et al., 2012), adopting the significance
level of p< 0.05. For all variables of the secondary outcomes, the
same analysis strategy will be used. Non-parametric tests will be
performed if some of the outcomes do not meet the conditions
necessary for parametric analysis.
Considering the different evaluations with the same cognitive
tests throughout the clinical trial, the improvement in the
performance of these tests may result from practice and not
from the intervention applied (Chelune, 2010; Goldberg et al.,
2015). A RCI will be used; it serves to assess whether the
changes identified comparing pre- and post-intervention data
can be attributed to the procedures used or are mere oscillations,
artifacts, or measurement errors (Jacobson and Truax, 1991)
resulting from repeated practice effects (Chelune et al., 1993).
The RCI, correcting for practice effects and using the Iverson’s
standard error of the difference will be calculated based on the
Duff’s (2012) formulae.
The follow-up analysis will calculate the primary outcome
(i.e., a decline in cognitive state). As proposed in Phase 1,
the same cutoff will be used to classify clinical improvement
(3.76 points in the mean, with an SD of 1.33 points in the
ADAS-cog). The primary outcome measure will be calculated
considering the differences between clinical improvement and
clinical relapse (or censored if relapse did not occur). Kaplan-
Meier survival analysis will be used to calculate this outcome. To
investigate interactions of risk factors, the following variables will
be observed: demographics characteristics (age, gender, level of
education), clinical condition (duration of illness, comorbidities
and neuropsychiatric states) and ‘‘methodological’’ variables
(Phase 1 group and crossover). The hazard ratio will be estimated
using the Cox proportional hazards (to each predictor variable or
covariate)’’
Regarding safety, adverse effects will be analyzed in terms
of the ratio in each group and period (before and after
treatment) and analyzed using Fisher’s exact test. Multivariate
regression will be used to identify predictors of response. The
outcome variables will be tDCS and cognitive intervention, and
the predictors will be age, gender, comorbidities and use of
medication.
The effectiveness of the blinding will be analyzed by using the
chi-square test, comparing the ratio between errors and correct
responses. Furthermore, these tests will be compared between
patients with clinical response and those who failed to improve.
Multivariate imputation by chained equations (MICE, the
R Foundation for Statistical Computing, Vienna, Austria; van
Buuren and Groothuis-Oudshoon, 2011) and the Statistical
Package for Social Sciences (SPSS) version 21 (IBM Corp.
Released, 2011, IBMr, SPSS Statistics version 21) software will
be used.
STEPWISE PROCEDURES
Figure 2 shows the stages of NeuroAD.
The phase I is a double-blind, randomized, factorial
clinical trial in which tDCS will be applied in parallel to
cognitive intervention in AD patients. This stage includes two
measurement time points: baseline (week 0) and post-treatment
(week 8). The data collection sessions will be performed
by treatment-blinded investigators including the primary and
secondary outcomes assessments. The pre-measurement consists
of a screening and measurement part. The screening part
contains data of the DSM-IV-TR, NINCDS-ADRDA criteria,
CDR, MMSE and health questionnaire (including questions
about disease duration, comorbidities and use of medication).
Adverse effects will be assessed at each session, wherein
the tDCS rater will ask the patients whether they feel any
discomfort or pain and whether this could be related to
tDCS.
Phase II is an open-label, crossover phase in which
non-responders from groups (2) and (4) (i.e., those receiving
sham tDCS) receive a course of active tDCS using the same
parameters and montage of phase I, that is, a direct current
of 2 mA (current density = 0.13 mA/cm2) for 30 min/day for
24 days, in respective six brain regions.
Phase III is the longitudinal study of NeuroAD in which
all active-tDCS responders—that is, responders from groups
(1) and (3) from phase I and responders from phase II
will be enrolled in a bi-monthly 1-year follow-up. Thus,
two months after the last session, the participants will receive
ten consecutive tDCS sessions (from Monday to Friday), which
will be repeated every other month, until completing a one-year
period (totaling 70 follow-up sessions). The tDCS parameters
will be the same as those applied during the period between
baseline and post-treatment, and the same cortical areas will be
stimulated.
The expected significant improvement is reaching 3.76 points
in the mean ADAS-Cog, with a SD of 1.32 points, according
to Rabey et al. (2013). Thus, we consider the difference
of at least three points in the ADAS-Cog and in the pre-
and post-treatment measures to be clinical improvement. All
participants with clinical improvement will be considered as
respondents.
In all steps, the primary and secondary outcomes assessments
will be repeated. The pre-intervention measurement is planned
to be performed in the week before the intervention starts and
the post-intervention measurement is planned for the first week
after the intervention.
ANTICIPATED RESULTS
Considering there is a serious lack of factorial designs for
clinical trials in non-invasive cerebral stimulation for AD
patients, we aim to ameliorate that situation by observing the
effect size and clinical effectiveness of each procedure, not
only comparing this intervention against a sham (which could
prove the efficacy, but not the clinical effectiveness), but also
against a cognitive intervention. Further, we hope to broaden
the treatment scope, promoting improvement in cognitive and
functional aspects by stimulating different cortical regions, in
addition to memory. Therefore, our study may generate key
results for clinical practice and patient management throughout
the disease.
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FIGURE 2 | Flowchart of phases I (double-blind factorial clinical trial), II (crossover) and III (follow-up) of the Neurostimulation combined with Cognitive Intervention in
Alzheimer’s disease (AD) Study (NeuroAD). T0: Baseline, pre-intervention measurement. T1–T8: intervention, tDCS and cognitive treatment. T9: endpoint,
post-intervention measurement.
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Then, to the best of our knowledge, our study may be the first
to apply a factorial design in non-invasive cerebral stimulation
for AD patients, and not only comparing this intervention
against a sham (which could prove the efficacy, but not the
clinical effectiveness), but also against a cognitive intervention.
Next, this factorial design will be able to observe the effect size
and clinical effectiveness of each procedure, and will also be able
to elucidate whether it would actually be feasible to apply the
therapies alone or in combination. Further, we hope to broaden
the treatment scope, promoting improvement in cognitive and
functional aspects by stimulating different cortical regions, in
addition to memory. Therefore, our study may generate key
results for clinical practice and patient management throughout
the disease.
An additional relevant issue is the longer-lasting effects.
Evidence shows that multisession protocols promote neural
plasticity and after-effects in AD and other conditions (Fregni
et al., 2015; Bystad et al., 2016b). Although a case study
that evaluated the effects of tDCS up to 8 months has been
reported in the literature (Bystad et al., 2017), we hope to
find that bimonthly stimulation sessions amplify the produced
effects. Likewise, the use of long-term physiological markers
will allow us to know what kind of non-pharmacological
therapies produce greater neuroplasticity effects in AD patients,
which are responsible for reaching and maintaining better
long-term overall performance. The implementation of
more effective procedures of plasticity induction in clinical
settings is essential—in fact, as a maintenance treatment
for bimonthly sessions, tDCS can offer the advantage of a
cost-effective approach (reducing missed visits) and a less
expensive alternative compared to daily sessions in the long-
term. In this way, our findings may also help improve the
recommendation management of AD.
Fundamentally, our study presents some methodological
limitations that should be discussed, including adherence.
The participants must come to our laboratory to receive
24 sessions three times a week. This may result in absences
due to transportation problems or personal difficulties. However,
different strategies will be adopted to minimize these problems,
such as flexible hours and frequent phone calls, encouraging
and reinforcing the importance of treatment. Also, we will set
a limit of missed appointments so that the treatment process
is less rigid, and the patient can resume the missed sessions
without compromising the treatment follow-up if necessary.
Second, applying the neuropsychological tests could elicit a
learning effect. The practice-adjusted RCI of the different
cognitive tests used in the clinical trial will be used to minimize
this limitation (Goldberg et al., 2015), as described in the
statistical analysis. Although some tests may have increased
susceptibility to practice effects (Calamia et al., 2012), patients
with AD show no significant effects in practice regarding
repeated administrations of different cognitive tests after a
test-retest interval (Cooper et al., 2004; Foley et al., 2015). A
third consideration is the inclusion of only mild AD patients,
thereby limiting the generalization to other phases of the disease.
Considering cognitive and functional differences between the
different stages of AD, we chose to evaluate patients at only
one stage of the disease for improved data control. However,
this does not preclude future studies comparing patients at
different stages of the disease to specifically clarify the best
dosage, procedure and number of tDCS sessions and cognitive
intervention, considering the clinical symptoms and disease
progression of the patients. Finally, although our proposition
is to stimulate different regions affected by AD, we cannot
assure that there will be no cumulative effects between them.
In view of intersubject and intrasubject variations, many studies
claim to have the focal power on tDCS, so we cannot rule
out the possibility of effect propagation from one region
to another (Boros et al., 2008; Cunningham et al., 2015).
As our study does not aim to evaluate or compare the
efficacy of tDCS at each site separately, cumulative effects
from synaptic connections between the involved regions may
result in improved cognitive and functional performance, and
not cause harm to patients. Nevertheless, it is important
to emphasize that we will use several strategies to control
bias, such as reduced electrode size, use of neuronavigation
to localize target regions in each patient, and the use of
standardized coordinates from previous studies for localizing
target regions.
In general, we hope that our results can elucidate the
relevance of such potential limitations. Additionally, we consider
that the current protocol together with our results will have
important implications for AD treatment, both theoretically in
providing support for new trials and for clinical management,
thus providing evidence applicable to the routine care of these
patients.
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